Parotid gland metastasis from prostate cancer: is docetaxel still the best treatment option?
Related Experiment Video
Updated: Sep 20, 2026
Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
Published on: September 8, 2017
Carole Hélissey1, Mathieu Rouanne, Francois-Xavier Arnaud
1Departments of aMedical Oncology bRadiology, Hôpital d'Instruction des Armées Val de Grâce cDepartment of Urology, Foch Hospital, Suresnes, Paris dUFR of Health Sciences, Université Versailles-Saint-Quentin-en-Yvelines, Versailles, France.
Abstract:
Metastases of prostate cancer originating from the parotid gland are rare. However, this presentation raises the question of the management of visceral metastasis in castration-resistant prostate cancer. We report the case of an 87-year-old man who presented with a right painless parotid mass in the context of castration-resistant prostate cancer, indicating progression of the disease. He received medical treatment based on docetaxel. Here, we discuss the impact of new hormonotherapies such as enzalutamide and abiraterone acetate, which may be used for the management of these patients.
